Stockreport

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

Mind Medicine (MindMed) Inc. - Common Shares  (MNMD) 
PDF --On track to initiate the Phase 3 Voyage study of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) in the fourth quarter of 2024; 12-week [Read more]